GLAZER CAPITAL, LLC

Position in APLS — Apellis Pharmaceuticals, Inc.

CIK 1076809 New York, NY

Back to APLS Full portfolio

Position in APLS

as of Mar 31, 2026 · filed May 14, 2026 Compact

Position Value

$0

New position

Shares Held

1,294,196

first reported quarter

Ownership

1.01%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2026

1 quarter on record

Voting authority Sole 100% Shared 0% None 0%

Derivatives in APLS

reported options exposure · as of Mar 31, 2026

CallValue

$0

CallShares

0

PutValue

$0

PutShares

1,632

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

GLAZER CAPITAL, LLC holds $237,076,682 across 5 Biotechnology names.

#	Ticker	Company	Shares	Value (USD)
1	APGE	Apogee Therapeutics, Inc.	1,641,042	$217,815,504
2	TECH	BIO-TECHNE Corp	200,000	$14,130,000
3	TBPH	Theravance Biopharma, Inc.	301,834	$5,131,178
4	CPRX	Catalyst Pharmaceuticals, Inc.	3,602,865	$0
5	NUVL	Nuvalent, Inc.	1,769,665	$0

2 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	—	1,632	—	Put	Sole	2026-05-14
2026-03-31	—	1,294,196	—	Shares	Sole	2026-05-14
No filing history on record for this holder in this stock.

GLAZER CAPITAL, LLC

Position in APLS

Derivatives in APLS

Position in Biotechnology

All Filings in APLS